ADA: Insulin efsitora noninferior to glargine for reducing HbA1c in adults with type 2 diabetes

Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among adults with type 2 diabetes, according to a study published online June 25 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 20 to 23 in Chicago.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup